BLRX Stock Summary and Trading Ideas (Bioline Rx | NASDAQ:BLRX)

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Bioline Rx trades on the NASDAQ stock market under the symbol BLRX.

As of September 9, 2026, BLRX stock price declined to $2.55 with 6,643 million shares trading.

BLRX has a beta of 1.37, meaning it tends to be more sensitive to market movements. BLRX has a correlation of 0.11 to the broad based SPY ETF.

BLRX has a market cap of $12.36 million. This is considered a Sub-Micro Cap stock.

Last quarter Bioline Rx reported $294,000 in Revenue and $.00 earnings per share. This fell short of revenue expectation by $-206,000 and exceeded earnings estimates by $.24.

In the last 3 years, BLRX traded as high as $93.20 and as low as $2.15.

BLRX has underperformed the market in the last year with a price return of -29.9% while the SPY ETF gained +18.7%. BLRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.5% and -10.5%, respectively, while the SPY returned +3.4% and -0.5%, respectively.

BLRX support price is $2.41 and resistance is $2.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLRX shares will trade within this expected range on the day.